research Elicitor mediated enhancement of wedelolactone in cell suspension culture of Eclipta alba (L.) Hassk
Adding yeast extract and methyl jasmonate to Eclipta alba cell cultures increased the production of the compound wedelolactone.
Search
for
Sort by
Research
510-540 / 1000+ results 
research Nanostructured Lipid Carriers Loaded with an Association of Minoxidil and Latanoprost for Targeted Topical Therapy of Alopecia
The new treatment using tiny lipid carriers to deliver minoxidil and latanoprost directly to hair follicles shows promise for alopecia.
research A combination of low-dose systemic etretinate and topical calcipotriol/betamethasone dipropionate treatment for hyperkeratosis and itching in Olmsted syndrome associated with a TRPV3 mutation
The combined treatment effectively managed severe skin issues in Olmsted syndrome.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Reporte de caso: alopecia areata universal tratada exitosamente con baricitinib
Baricitinib successfully treated severe hair loss.
research Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
Baricitinib might help treat hair loss in lupus patients, but more research is needed.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Alopesia universalis pada anak yang berespon baik dengan terapi kombinasi: sebuah laporan kasus
A young child with complete hair loss improved significantly with a combination of hair growth treatments and laser therapy.
research Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Acute Bullous Dermatosis and Onycholysis due to High-Dose Methotrexate and Leucovorin Calcium
High-dose methotrexate can cause severe skin and nail issues.
research Imatinib-induced classical lichen planopilaris in blaschko-linear distribution leading to cicatricial alopecia
Imatinib can cause hair loss due to lichen planopilaris.
research Hair Lightening of Three Hemodialysis Patients Under Heptaminol
Heptaminol may cause hair lightening in hemodialysis patients.
research Pantolactams as androgen receptor antagonists for the topical suppression of sebum production
Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
research Valproate-induced change in hair color
Valproic acid can cause hair loss, but information on hair color change is not detailed.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
research Sodium Metabisulfite: Effects on Ionic Currents and Excitotoxicity
Sodium metabisulfite increases sodium channel activity, leading to higher cell excitability and potential damage.
research Efficacy and safety of Latilactobacillus curvatus LB-P9 on hair health: a randomized, double-blind, placebo-controlled clinical trial
LB-P9 supplements improve hair health and satisfaction without side effects.
research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Tacrolimus in Dermatologic Disorders
Topical tacrolimus is safe and effective for skin conditions, but oral tacrolimus has serious side effects.
research A 2018 Approach to Combating Methotrexate Toxicity Folic Acid and Beyond.
New strategies like vitamin A and dextromethorphan can help reduce methotrexate side effects and improve patient adherence.
research Hyperpigmentation, severe alopecia, and six days of instability in a case of severe methotrexate hypersensitivity reaction
A woman had severe reactions to methotrexate, including skin issues and organ problems, but improved after 38 days in the hospital.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Low‐dose oral minoxidil in female patients with lichen planopilaris: Real‐life experience
research Inhibitory effect of tianeptine on catagen induction in alopecia areata-like lesions induced by ultrasonic wave stress in mice
Tianeptine, an antidepressant, may prevent stress-induced hair loss in mice.
research Comparative study of the action of dynamized forms of melatonin and lissotriton
Melatonin and Lissotriton improved hair quality and increased activity in mice.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.